

---

**From:** Clapp Mike GBAP  
**Sent:** Thursday, May 15, 2003 4:42 PM  
**To:** Wheals Ian CHBS; Wilks Martin CHBS; Scott David W CHBS  
**Cc:** Street John CHBS; Voerman Michael CHBS; Vitolo David CHBS; Barnes Jasper CHBS  
**Subject:** RE: PP796 and interest from Bayer

Ian,  
As you are aware much of our data is to demonstrate effectiveness in gramoxone formulations and it is these studies rather than toxicology of emetic per se which has been the main emphasis of regulatory submissions. Plus at least one review of the human data.  
The database on the emetic per se is relatively old and limited. Currently being reviewed - a task we had identified previously to decide if we needed to update any studies for longer term maintenance of registrations.  
Bayer would need to demonstrate effectiveness in their formulations since formulation type can influence availability and effectiveness would depend upon site of absorption of the aldicarb in the gi tract.  
Assume you do not need bibliography of studies available etc at this time.  
Mike

-----Original Message-----

**From:** Wheals Ian CHBS  
**Sent:** 14 May 2003 16:04  
**To:** Wilks Martin CHBS; Clapp Mike GBAP; Scott David W CHBS  
**Cc:** Street John CHBS; Voerman Michael CHBS; Vitolo David CHBS; Barnes Jasper CHBS  
**Subject:** PP796 and interest from Bayer  
**Importance:** High

Folks,

Bayer have apparently approached us about using PP796 in aldicarb formulations. Are you aware of this ?, I wasn't until now.

<< Message: FW: Gramoxone Emetic (PP796) >>

It raises a number of potential concerns and I would appreciate your comments

- Potential to focus unhelpful attention on the specific contribution of the emetic rather than the combination of safening agents in Gramoxone
- May trigger increased scrutiny of the inclusion level of PP796 relative to ai toxicity
- May focus increased attention on the specification and regulatory package for PP796 supporting its inclusion in Gramoxone
- May attract external investment in PP796 manufacture increasing availability for PQ generics, (conversely could off-set cost of Syngenta manufacture)

Please could you let me have your comments.

Thanks,

Ian